Nerida Scott

Ligand UK Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market, Moxatag, a once-a-day formulation of the antibiotic and amoxicillin, and frovatriptan, used for the acute treatment of migraine. It also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom.

RespiVert Ltd. operates as a small molecule drug discovery company. The firm develops small-molecule inhaled therapies for the treatment of chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. The company was founded by William Garth Rapeport, Peter Strong, Kazuhiro Ito, John Murray and Peter Barnes in 2007 and is headquartered in London, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Johnson & Johnson Innovation Ltd is a private equity subsidiary of Johnson & Johnson Innovation - JJDC, Inc. founded in 2000. The firm is headquartered in Buckinghamshire, United Kingdom.

XO1 Ltd. develops a novel anticoagulant drug. The firm operates as a biopharmaceutical company. The company was founded by David J. Grainger on February 28, 2013 and is headquartered in High Wycombe, the United Kingdom.